Kobe, Japan

Kayo Hatanaka


Average Co-Inventor Count = 3.3

ph-index = 3

Forward Citations = 40(Granted Patents)


Location History:

  • Kobe, JP (1999)
  • Hyogo-ken, JP (2000)

Company Filing History:


Years Active: 1999-2000

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Kayo Hatanaka: Innovator in Hematology

Introduction

Kayo Hatanaka is a prominent inventor based in Kobe, Japan. She has made significant contributions to the field of hematology, particularly in the detection and classification of blood cells. With a total of 3 patents, her work has advanced the understanding of erythrocyte morphology and leukocyte classification.

Latest Patents

Hatanaka's latest patents include a method for detecting abnormal morphology of erythrocytes. This innovative method allows for the identification of abnormalities in erythrocyte structure, which is crucial for diagnosing various blood disorders. Another notable patent is a method for classifying and counting immature leukocytes. This technique involves treating a hematological sample with a hemolytic agent that preserves immature leukocytes while damaging other types. The damaged leukocytes are then stained with a fluorochrome, enabling precise measurement and classification based on scattered light and fluorescence intensities.

Career Highlights

Throughout her career, Kayo Hatanaka has worked with leading companies in the medical technology sector. Notably, she has been associated with Sysmex Corporation and Toa Medical Electronics Co., Ltd. Her work in these organizations has contributed to the development of advanced diagnostic tools in hematology.

Collaborations

Hatanaka has collaborated with esteemed colleagues such as Takashi Sakata and Yuji Itose. These partnerships have fostered innovation and have been instrumental in her research endeavors.

Conclusion

Kayo Hatanaka's contributions to hematology through her patents and collaborations highlight her role as a key innovator in the field. Her work continues to impact the diagnosis and treatment of blood-related conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…